

# **Abstract Submission Form**

The Women's Heart Center Program Committee is accepting abstract submission forms through **August 15**, **2025**. Completed forms should be emailed to <a href="https://www.whc.emailed.com"><u>WHC@TheChristHospital.com</u></a>.

Abstract submissions should be gender- and sex-specific research pertaining to one of the program topics outlined below.

The Program Committee wishes to encourage young scientific investigators and will reward up to 4 abstracts/posters submitted by presenters considered early career (definition provided below). First place will receive \$1000, second place will receive \$500, and two honorable mentions will each receive \$250.

The presenting author will be sent an email with the status of the submission by **August 22**, **2025**. If your abstract is accepted, your notification will contain complete presentation information. However, please note the following:

- All human subject research must conform to the principles of the Declaration of Helsinki of the World Medical Association.
- The presenting author should be able to provide documentation of IRB approval if requested.
- The Program Committee is unable to reimburse presenters for travel, hotel, or per diem expenses.
- Submission of an abstract constitutes a commitment by the presenting author (or designee) to present inperson at the symposium on October 3, 2025, during the following times:
  - o Registration & Networking: 7:00 8:00 am
  - o Networking Lunch: 12:00 1:30 pm
  - o Poster Session Award Announcement: 4:50 5:10 pm
- All accepted abstract presenters must register for the symposium via Eventbrite and pay the applicable registration fees (trainees and invited speakers will have the registration fee waived).
- If an author wishes to withdraw an abstract, please email <u>WHC@TheChristHospital.com</u>.

Presenting Author Info								
Name (First, Last, Credentia Institutional Affiliation: Insp								
Email Address: dharajrana@								
	_		udents, a	nd other healt	heare providers currently in residency			
or fellowship programs or w	•			Yes 🛭	- · · · · · · · · · · · · · · · · · · ·			
Co-author Information	1							
Name: Dhara Rana, DO	e: Dhara Rana, DO Email: dharajrana@gmai			.com Affiliation: Inspira Medical Center Vineland				
Name: Laith Abwini, DO	Email: AbwiniL@ihn.org		Affiliation: Inspira Medical Center Vineland					
Name: Nabeel Sami, DO Hospital	Email: wia9042@nyp.org		Affiliation: New York-Presbyterian Brooklyn Methodist					
Name: Lin Zheng, DO	Email: zhengl@ihn.org		Affiliation: Inspira Medical Center Vineland					
<b>Disclosures:</b> Please list an None	ny relevant	financial disclosure	es.					
Abstract Topic (must b	e gende	r- or sex-specific	e)					
☐ Preventative cardiology		⊠ General cardio	ology	[	☐ Interventional cardiology			
☐ Heart failure		☐ Cardio-oncology		[	☐ Cardio-obstetrics			
☐ Electrophysiology		☐ Cardiovascular Imaging		ıg [	☐ Coronary Microvasculature			
☐ Social Determinants of Health		☐ Mental Health		[	☐ Precision Medicine			
<b>Title:</b> Include the full title	as it will a	nnear on the noster						
			ortic Sten	nosis of Patients	s Undergoing Hip Fracture Repair			
study, preferably in no more Hip fractures (HFx) are a comn	than two	to three sentences.  of hospitalization in th	ne elderly,	, disproportion	he background and purpose of the ately affecting women but associated at aortic stenosis (AS), surgical risk is			

substantially increased, yet the optimal management strategy and the influence of gender on outcomes remain unclear.

#### **Methods:** Briefly state the methods used.

We conducted a retrospective analysis of the National Inpatient Sample (2019–2022) to evaluate sex-specific differences in postoperative outcomes among patients with AS undergoing hip fracture surgery. Survey-weighted logistic regression models were used to assess associations between sex and in-hospital mortality and complications, adjusting for demographics and comorbidities. Interaction and stratified analyses further examined sex-based effect modification.

### **Results:** Summarize the results in sufficient detail to support the conclusions.

Among 114,814 patients who underwent hip fracture surgery, 2,775 (2.42%) had a diagnosis of aortic stenosis (AS), with females comprising 60.7% of the AS cohort. In multivariable regression, female sex was independently associated with lower inhospital mortality among AS patients (adjusted odds ratio [aOR] 0.62, 95% CI 0.55–0.70; p < 0.001). There was no significant interaction between sex and AS on mortality (p = 0.735). Compared to males, females with AS had lower odds of acute myocardial infarction (aOR 0.68), pulmonary edema (aOR 0.18), and delirium (aOR 0.65). In sex-stratified models, coronary artery disease, malnutrition, and end-stage renal disease were consistently associated with complications in both sexes.


Click or tap here to enter text.

#### **Conclusions:** Concisely state the conclusions reached.

Female sex is associated with reduced in-hospital mortality and fewer complications in patients with AS undergoing hip fracture surgery. However, underlying comorbidities exert sex-specific effects, warranting tailored perioperative risk assessment and management strategies.

**Tables/Figures/Graphics:** Include images that are part of your submission here. Images should be high resolution and have a file type of "gif", "jpg", or "jpeg".

Figure 1: Study Design



## Table :

			Aortic Stenosis		
		Patients, Number (%)	Present	Absent	P value
Characteristics			114,814 2,775 (2.42)	112039 (97.58)	
				440000000	
Age	e, mean (SD),y		84.4 (6.8)	77.3 (14.3)	40.001
Age groups,y					< 0.001
18-	54	4,685 (4.22)	31(1.1)	4,839 (4.3)	
55-		9,827(8.86)	38(1.4)	10,129(9.0)	
65-		23,445 (21.13)	249(9.0)	23.991(21.4)	
75-		38,551 (34.75)	832(30.0)	39,036(34.9)	
>85		34,440 (31.04)	1,652 (59.6)	34,044(30.3)	
Sex		34,440 (31,04)	1,002 (00.0)	34,044(30.3)	<0.001
	male	70 107 (00 27)	1.686 (60.8)	74.501(66.5)	0.001
Mai		76,187 (66.37)			
Race	ie	38,607 (33.63)	1,089 (39.2)	37,518(33.5)	0.0006
Wh	it in	00.074/00.51	2 44 4 (02 4)	04 500/00 4)	0.0000
	7	96,974 (86.5)	2,414 (89.1)	94,560 (86.4)	
Bla		5,331 (4.8)	86 (3.2)	5,245 (4.8)	
Oth	panic	5,039 (4.5)	99 (3.7)	4,940 (4.5)	
Comorbidities		4,747 (4.2)	110 (4.1)	4,637 (4.2)	
E CONTRACTOR OF THE PARTY OF TH	pertension	52,459 (45.7)	1031 (37.2)	51428(45.9)	<0.001
Une	complicated Diabetes	10,597 (9.23)	255 (9.2)	10,342 (9.2)	0.9394
Cor	mplicated Diabetes	15,947 (13.9)	15,440 (13.8)	507 (18.3)	<0.0001
Plu	monaryHTN	4,897 (4.27)	318 (11.46)	4,579(4.09)	<0.0001
	rnary Artery Disease	529(0.46)	506 (0.5)	23 (0.8)	0.0038
	g term anticoaguation	16,495 (14,37)	15,944 (14.2%)	551 (19.9%)	<0.0001
	ronic kidney Disease	14,152(12.33)	13,588 (12.1%)	564 (20.3%)	<0.0001
End	d stage renal disease	1,932 (1.68)	1,865 (1.7%)	67 (2.4%)	0.0022
Mai	lignancy	3,359 (2.93)	3,274 (2.9%)	85 (3.1%)	0.6866
	esity	6,681 (5.82)	6,512 (5.8%)	169 (6.1%)	0.5387
Alc	ohol Abuse	4995 (4.35)	50(1.8)	4945 (4.41)	<0.0001
Ata	xia	0 (0.0)	0 (0.0)	0(0.0)	-
Ost	teoporosis	15,175 (13.22)	335 (12.07)	14840(13.25)	0.0703
Vita	amin D deficiency	0 (0.0)	0 (0.0)	0(0.0)	_
	tein energy malnutrition	3841 (3.35)	122(4.4)	3719(3.32)	0.0016
	mentia	0 (0.0)	0 (0.0)	0(0.0)	_
	teoarthritis	1599 (1.39)	50(1.8)	1,549 (1.38)	0.0601
	eumatoid arthritis	3,145(2.74)	57(2.05)	3,088(2.76)	0.0266
	ok ing	627 (.55)	6(0.22)	621(0.55)	0.0171
	ronic obstructive pulmonary disease	24,382(21.24)	663(23.89)	23,719 (21.17)	0.0005
lix hauser groups			= 7-1-1-1		<0.0001
<4		64,918 (56.5)	596(21.48)	64322 (57.41)	2,0002
4-6		40,549 (35.32)	1,475(53.15)	39,074(34.88)	
>6		9347 (8.14)	704(25.37)	8,643(7.71)	
Insurance status		(8.5-1)			<0.001
	dicare	94,237 (82.2)	2,541 (91.7)	91,696 (81.9)	
	dicaid	4,044 (3.5)	30(1.1)	4,014 (3.6)	
	vate	11,913(10.4)	144(5.2)	11,769 (10.5)	
	vate	4,486 (3.9)	56(2.0)	4,430 (4.0)	
Hospital Bed Size		יון יין טיאן די	JU12.W	4,450 [4.0]	0.7846
Sm	all	28,213 (24.57)	666(24)	27547 (24.59)	0.7040
	dium	34765 (30.28)	846(30.49)	33,919(30.27)	
Lar		51,836 (45.15)	1,263(45.51)	50,573 (45.14)	
	85	51,030(40.13)	1,203(40.01)	30,073 (40.14)	
Hosital Location		40 555/44 241		40 000 000 000	0.0058
rura		13,555 (11.81)	277 (9.98)	13,278 (11.85)	
urb	an, nonteaching	24,367 (21.22)	577 (20.79)	23,790 (21.23)	
	an teaching	76,892 (66.97)	1,921 (69.23)	74,971 (66.92)	

## Table 2

		Female  Aortic Stenosis		P value		Male  Aortic Stenosis		P value
	Patients, Number(%)							
		Present	Absent		Patients, Number(%)	Present	Absent	
	76,187	1,686 (2.21%)	74,501 (97.8%)		38,607	1,089(2.82%)	37,518 (97.2%)	
Length of stay - days Median (IQR)		5 [4-7]	4 [3-6]	<0.001		5 [4-8]	5 [3-7]	< 0.001
In hospital Deaths	719 (0.94)	30 (1.8)	689 (0.9)	0.000	3 660 (1.71)	33 (3.0)	627 (1.7%)	0.0006
Total Hospital Charges		94,107 (±1,745)	85,066 (±477)	<0.001		100,010 (±2,17	94,881 (±671)	0.019
Acute Myocardial Infarction	3,643 (4.8%)	116 (6.9%)	3,527 (4.7%)	0.000	3,186 (8.3%)	120 (11.0%)	3,066 (8.2%)	0.0008
Acute Pulmonary edema	147 (0.2%)	3 (0.2%)	144 (0.2%)	0.886	90 (0.2%)	8 (0.7%)	82 (0.2%)	0.0005
Cardiogenic shock	125 (0.2%)	7 (0.4%)	118 (0.2%)	0.010	1 83 (0.2%)	11 (1.0%)	72 (0.2%)	< 0.0001
Acute DVT/Pulmonary embolism	457 (0.6%)	12 (0.7%)	445 (0.6%)	0.546	2 230 (0.6%)	6 (0.6%)	224 (0.6%)	0.8456
Septic shock	175 (0.2%)	5 (0.3%)	170 (0.2%)	0.561	3 206 (0.5%)	6 (0.6%)	200 (0.5%)	0.9364
Pneumonia	11 (0.01%)	0 (0%)	11 (0.01%)	0.617	17 (0.04%)	0 (0%)	17 (0.04%)	0.4808
Acute Respiratory failure	175 (0.2%)	5 (0.3%)	170 (0.2%)	0.561	3 206 (0.5%)	6 (0.6%)	200 (0.5%)	0.9364
Acute Ischemic CVA	231 (0.3%)	6 (0.4%)	225 (0.3%)	0.691	1 139 (0.4%)	5 (0.5%)	134 (0.4%)	0.5795
Acute Renal failure	12 (0.02%)	0 (0%)	12 (0.02%)	0.600	18 (0.05%)	1 (0.1%)	17 (0.05%)	0.4837
Acute Delirium	4,414 (5.8%)	132 (7.8%)	4,282 (5.7%)	0.0003	3 2,668 (6.9%)	122 (11.2%)	2,546 (6.8%)	< 0.0001
Post operative SS infection	15 (0.02%)	0 (0%)	15 (0.02%)	0.558	2 13 (0.03%)	0 (0%)	13 (0.03%)	0.5392
Post operative bleeding	17 (0.02%)	0 (0%)	17 (0.02%)	0.534	7 (0.02%)	0 (0%)	7 (0.02%)	0.6528